目录:MedChemExpress LLC>>生化试剂>> Lurbinectedin | MCE
CAS | 497871-47-3 | 纯度 | 99.80% |
---|---|---|---|
分子量 | 784.87 | 分子式 | C₄₁H₄₄N₄O₁₀S |
供货周期 | 现货 | 规格 | 1 mg |
货号 | HY-16293 | 应用领域 | 医疗卫生,化工,生物产业,制药/生物制药 |
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 497871-47-3
产品活性:Lurbinectedin (PM01183) is a DNA minor groove covalent binder with potent anti-tumour activity; inhibits RMG1 and RMG2 cell growth with IC50 values of 1.25 and 1.16 nM, respectively.
研究领域:Cell Cycle/DNA Damage
作用靶点:DNA Alkylator/Crosslinker | DNA/RNA Synthesis
In Vitro: PM01183 is a new synthetic tetrahydroisoquinoline alkaloid that is currently in phase I clinical development for the treatment of solid tumours. PM01183–DNA adducts in living cells give rise to double-strand breaks, triggering S-phase accumulation and apoptosis. The potent cytotoxic activity of PM01183 is ascertained in a 23-cell line panel with a mean GI50 value of 2.7 nM. Lurbinectedin exhibits significant antitumor activity toward chemosensitive and chemoresistant human ovarian clear cell carcinoma (CCC) cells in vitro.
In Vivo: Mouse CCC cell xenografts reveals that lurbinectedin significantly inhibits tumor growth. Lurbinectedin plus SN-38 results in a significant synergistic effect. In four murine xenograft models of human cancer, PM01183 inhibits tumour growth significantly with no weight loss of treated animals. Single lurbinectedin or NSC 119875-combined therapies are effective in treating NSC 119875-sensitive and NSC 119875-resistant preclinical ovarian tumor models. The strongest synergistic effect is observed for combined treatments, especially in NSC 119875-resistant tumors. Lurbinectedin tumor growth inhibition is associated with reduced proliferation, increased rate of aberrant mitosis, and subsequent induced apoptosis.
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | Bioactive Compound Library Plus | IBU-DC Phosphoramidite | 2,4-D sodium salt | Thailanstatin D | Busulfan | Carboplatin-d4 | Caracemide | Farudodstat | DNA31 | 2'-OMe-Ac-C Phosphoramidite | Dasabuvir | DNA Gyrase-IN-4 | Uridine triphosphate-13C9,15N2 (sodium) | 5-Methylcytosine | Cidofovir dihydrate | Capecitabine-d11 | Tezacitabine | Mequindox | (+)-CBI-CDPI1 | 2-Iodoacetamide | 5-Methylcytosine-d4 | Duocarmycin GA | TH287 hydrochloride | DNA Gyrase-IN-1 | 2'-O-MOE-5-Me-rU | Palifosfamide tromethamine | Levofloxacin sodium | GC7 Sulfate | Mipicoledine | Psammaplin A | hDHODH-IN-2
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种*仅有化合物库,我们致力于为*科研客户提供前沿的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药 Patent 收录了MCE客户的科研成果;
• 专业团队跟踪新的制药及生命科学研究进展,为您提供*新的活性化合物;
• 与世界各大制药公司及*科研机构建立了长期的合作。